结核病亚单位疫苗的临床研究进展

Progress of tuberculosis subunit vaccine in clinical research

结核病是造成全世界成年人死亡的主要传染病,在过去25年里也一直是全球公共卫生的挑战。目前唯一批准的结核疫苗只有卡介苗,因此开发安全有效的新型结核疫苗任重而道远。重组亚单位疫苗成分明确、安全性高、可诱导高效的免疫应答、提供长期的免疫保护效果,因而具有较好的应用前景。本文针对结核病重组亚单位疫苗的组分、临床研究现状、应用等方面的进展进行综述。

Tuberculosis is still the main infectious disease that causes adult deaths worldwide and has been a global public health challenge for the past 25 years.At present,the only approved tuberculosis vaccine is BCG and there is still a long way to go to develop safer and more effective vaccine of tuberculosis.Recombinant subunit vaccines have clear components,high safety,can induce high-efficiency immune responses,and provide long-term immune protection effects.So they have good application prospects.This article reviewed the progress in the components,clinical research status,and application of the tuberculosis recombinant subunit vaccine.